Efficacy of dasatinib against ponatinib-resistant chronic myeloid leukemia cells

Seiichi OkabeDepartment of Hematology, Tokyo Medical University, Tokyo, JapanCorrespondence[email protected]
View further author information

Yuko TanakaDepartment of Hematology, Tokyo Medical University, Tokyo, JapanView further author information

Mitsuru MoriyamaDepartment of Hematology, Tokyo Medical University, Tokyo, JapanView further author information

Akihiko GotohDepartment of Hematology, Tokyo Medical University, Tokyo, JapanView further author information

Click to increase image sizeClick to decrease image size

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This work was supported by a High-Tech Research Center Project for Private Universities, a matching fund subsidy from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), and by the University-Industry Joint Research Project for Private Universities, a matching fund subsidy from MEXT. This work was also supported by Grants-in-Aid for Scientific Research from MEXT.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Efficacy of dasatinib against ponatinib-resistant chronic myeloid leukemia cells

Information for

Open access

Opportunities

Help and information

Efficacy of dasatinib against ponatinib-resistant chronic myeloid leukemia cells

Disclosure statement

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature